Physician profile
Kevin Collier
NPI 1730287228
$12,294.41
in general payments reported to CMS, 2019-2025
45 companies · $2,947 in 2025
The $2,947 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $299 · 2021: $583 · 2022: $1,368 · 2023: $3,072 · 2024: $2,620 · 2025: $2,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,622 · Education: $17.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,622.46 |
| Education | $17.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,668.26 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,458.12 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $850.71 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $842.90 | 2021-2024 | Zeposia |
| Pfizer INC. | $695.56 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $657.25 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $612.54 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $597.62 | 2022-2025 | |
| Qol Medical, LLC | $596.05 | 2019-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $338.07 | 2019-2025 | General - Endochoice, Speedband Superview Super 7 |
| Regeneron Healthcare Solutions, INC. | $334.89 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $304.61 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $216.74 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $206.36 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $203.07 | 2019-2025 | Rebyota |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.